No results for ‘’
Glenmark Pharmaceuticals Ltd
₹2379
(1.12%)
Mon, 25 May 2026, 07:53 am
Health Technology
Pharmaceuticals: Major
24.5KGlenmark Pharmaceuticals Share Price Live Chart
1 Day
(1.12%)
No Result Found
Summary
Market Cap
63754.81
Net Profit
1047.14
P/B
4.91
Sector P/E
34.11
P/E
41.50
EV/EBITDA
21.14
Debt/Equity (Industry)
0.16
Interest Cover (Industry)
17.01
ROCE (Industry)
16.41
RONW (Industry)
14.52
ROE
15.79
ROCE
18.48
Debt/Equity
0.22
EPS (TTM)
95.92
Dividend Yield
0.11
Book Value
339.54
Interest Cover
9.56
Analysis
all
- Dividends per share have increased over the past 10 years.
- Dividends paid are thoroughly covered by earnings (12.7x coverage).
- Dividends after 3 years are expected to be thoroughly covered by earnings (13.5x coverage).
- Dividends per share have been stable in the past 10 years.
- Glenmark Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 7.2%.
- Glenmark Pharmaceuticals's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
- Glenmark Pharmaceuticals's dividend is below the markets top 25% of dividend payers in India (3.08%).
- Cash flow for Glenmark Pharmaceuticals is expected to decrease over the next 2 years.
- Glenmark Pharmaceuticals's earnings are expected to grow by 14.2% yearly, however this is not considered high growth (20% yearly).
- Glenmark Pharmaceuticals's earnings growth is positive but not above the India market average.
Shareholding
| Shareholders | MAR 2026 | DEC 2025 | SEPT 2025 | JUN 2025 | MAR 2025 |
|---|---|---|---|---|---|
| Promoters | 46.65 | 46.65 | 46.65 | 46.65 | 46.65 |
| FII | 20.34 | 19.20 | 20.73 | 20.62 | 23.16 |
| DII | 19.29 | 20.09 | 18.61 | 17.64 | 14.60 |
| Public | 13.68 | 14.02 | 13.97 | 15.06 | 15.56 |
| Government | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 |
Technical Analysis
Support and Resistance
| Type | R3 | R2 | R1 | PP | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | 3297.27 | 2789.77 | 2598.03 | 2282.27 | 2090.53 | 1774.77 | 1267.27 |
| Fibonacci | 2789.77 | 2595.90 | 2476.13 | 2282.27 | 2088.40 | 1968.63 | 1774.77 |
| Camarilla | 2545.86 | 2499.34 | 2452.82 | 2282.27 | 2359.78 | 2313.26 | 2266.74 |
Pivots Level: Classic
R3
+1015
3297.27
R2
+507.50
2789.77
R1
+315.77
2598.03
S1
-191.73
2090.53
S2
-507.50
1774.77
S3
-1015
1267.27
Moving Average
Period
Value
10-EMA
2339.89
20-EMA
2328.82
30-EMA
2306.43
50-EMA
2259.26
100-EMA
2169.15
200-EMA
2041.48
Corporate Actions
| Announcement Date | Purpose | Action | Ex Date |
|---|---|---|---|
| 30 Jan 2026 | board-meetings | Quarterly Results | |
| 14 Nov 2025 | board-meetings | Quarterly Results | |
| 26 Sept 2025 | dividend | ₹2.50 Dividend /Share | 03 Oct 2025 |
| 03 Sept 2025 | dividend | Interim Dividend - Rs. - 2.5 | 03 Oct 2025 |
| 22 Aug 2025 | agm | ||
| 15 Aug 2025 | dividend | Final Dividend - Rs. - 2.5 | 15 Sept 2025 |
| 23 May 2025 | dividend | ₹2.50 Dividend /Share | 15 Sept 2025 |
| 30 Aug 2024 | agm | ||
| 13 Aug 2024 | dividend | Dividend - Rs 2.50 Per Share | 17 Sept 2024 |
| 24 May 2024 | dividend | ₹2.50 Dividend /Share | 17 Sept 2024 |
Peer Comparison
Glenmark Pharmaceuticals Ltd
Divis Laboratories Ltd
Sun Pharmaceutical Industries Ltd
Cipla Ltd
Dr Reddys Laboratories Ltd
Torrent Pharmaceuticals Ltd
Glenmark Pharmaceuticals Ltd About
Glenmark Pharmaceuticals is engaged in the business of development, manufacturing and marketing of pharmaceutical products both formulation and active pharmaceuticals ingredient to regulated and semi-regulated markets.
Industry
Pharmaceuticals - Indian - Bulk Drugs & Formln
Founded
1977
Headquarters
CEO
Glenn Saldanha
Employees
Contact
Website
http://www.glenmarkpharma.com
complianceofficer@glenmarkpharma.com
Phone
91-22-40189999
Location
B/2 Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai, Maharashtra, 400026
Glenmark Pharmaceuticals Ltd Company History
| Year | History |
|---|---|
| 2020 |
|
| 2021 |
|
| 2022 |
|
| 2023 |
|
| 2024 |
|
Deals
| Client Name | Deal Type | Order Side | QTY | Avg Price | Date |
|---|---|---|---|---|---|
| GRAVITON RESEARCH CAPITAL LLP | bulk | Sell | 1510591 | 2173.31 | 11 Jul 2025 |
| GRAVITON RESEARCH CAPITAL LLP | bulk | Buy | 1510591 | 2171.67 | 11 Jul 2025 |
| INTEGRATED CORE STRATEGIES (ASIA) PTE. LTD. | block | Buy | 264465 | 1492.65 | 25 Mar 2025 |
| UBS AG | block | Sell | 264465 | 1492.65 | 25 Mar 2025 |
| UBS PRINCIPAL CAPITAL ASIA LIMITED | block | Sell | 671394 | 1510 | 23 Jan 2025 |
| UBS AG | block | Buy | 671394 | 1510 | 23 Jan 2025 |
| ISHARES MSCI INDIA SMALL-CAP ETF | block | Buy | 39265 | 397.9 | 25 Oct 2022 |
| ISHARES CORE MSCI EMERGING MARKETS ETF | block | Buy | 302621 | 397.9 | 25 Oct 2022 |
| ISHARES CORE EMERGING MARKETS MAURITIUS CO | block | Sell | 302621 | 397.9 | 25 Oct 2022 |
| ISHARES INDIA SC MAURITIUS COMPANY | block | Sell | 39265 | 397.9 | 25 Oct 2022 |